Membrane Proteome Array (MPA)

SR Swetha Raman
SB Samantha N. Buongervino
ML Maria V. Lane
DZ Doncho V. Zhelev
ZZ Zhongyu Zhu
HC Hong Cui
BM Benjamin Martinez
DM Daniel Martinez
YW Yanping Wang
KU Kristen Upton
KP Khushbu Patel
KR Komal S. Rathi
CN Carmen T. Navia
DH Daniel B. Harmon
YL Yimei Li
BP Bruce Pawel
DD Dimiter S. Dimitrov
JM John M. Maris
JJ Jean-Philippe Julien
KB Kristopher R. Bosse
ask Ask a question
Favorite

The MPA was conducted at Integral Molecular, Inc. and is a protein library composed of over 6,000 distinct human membrane protein clones, each overexpressed in live HEK293T cells from expression plasmids. Each clone was individually transfected in separate wells of a 384-well plate followed by a 36-hour incubation.42 Cells expressing each individual MPA protein clone were arrayed in duplicate in a matrix format for high-throughput screening. Before screening on the MPA, the D3-GPC2-IgG1 antibody concentration for screening was determined on cells expressing positive (membrane-tethered Protein A and GPC2) and negative (mock-transfected) binding controls, followed by detection by flow cytometry using a fluorescently-labeled secondary antibody. The D3-GPC2-IgG1 antibody was then added to the MPA at the predetermined concentration, and binding across the protein library was measured on an Intellicyt iQue using a fluorescently-labeled secondary antibody. Each array plate contains both positive (Fc-binding) and negative (empty vector) controls to ensure plate-by-plate reproducibility. D3-GPC2-IgG1 antibody interactions with any targets identified by this MPA screening were validated in a second flow cytometry experiment using serial dilutions of the test antibody, and the target identity was re-verified by sequencing. Figure 3L shows all the validated hits using this approach for the D3-GPC2-IgG1 antibody.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A